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A B S T R A C T
Secreted frizzled-related protein (sFRP) 4 is an adipokine with increased expression in white adipose tissue from
obese subjects with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Yet, it is unknown whether
sFRP4 action contributes to the development of these pathologies. Here, we determined whether sFRP4 ex-
pression in visceral fat associates with NAFLD and whether it directly interferes with insulin action and lipid and
glucose metabolism in primary hepatocytes and myotubes. The association of sFRP4 with clinical measures was
investigated in obese men with or without type 2 diabetes and with or without biopsy-proven NAFLD. To de-
termine the impact of sFRP4 on metabolic parameters, primary human myotubes (hSkMC), or primary hepa-
tocytes from metabolic healthy C57Bl6 and from systemic insulin-resistant mice, i.e. aP2-SREBP-1c, were used.
Gene expression of sFRP4 in visceral fat from obese men associated with insulin sensitivity, triglycerides and
NAFLD. In C57Bl6 hepatocytes, sFRP4 disturbed insulin action. Specifically, sFRP4 decreased the abundance of
IRS1 and FoxO1 together with impaired insulin-mediated activation of Akt-signalling and glycogen synthesis and
a reduced suppression of gluconeogenesis by insulin. Moreover, sFRP4 enhanced insulin-stimulated hepatic de
novo lipogenesis (DNL). In hSkMC, sFRP4 induced glycolysis rather than inhibiting insulin signalling. Finally, in
hepatocytes from aP2-SREBP-1c mice, sFRP4 potentiates existing insulin resistance. Collectively, we show that
sFRP4 interferes with hepatocyte insulin action. Physiologically, sFRP4 promotes DNL in hepatocytes and gly-
colysis in myotubes. These sFRP4-mediated responses may result in a vicious cycle, in which enhanced rates of
DNL and glycolysis aggravate hepatic lipid accumulation and insulin resistance.
1. Introduction
In obesity, the adipose tissue expands due to an enhanced storage of
lipids in white adipocytes. Yet, an impaired lipid storage capacity of the
adipose tissue contributes to increased lipid deposition in non-adipose
tissues, including the liver. Ectopic lipid distribution may result from
excess caloric intake resulting in obesity, but also characterizes dis-
orders associated with impaired lipid storage capacity, such as lipody-
strophies [1]. Obesity alters the secretion of hormones, called adipo-
kines, from adipose tissue and alterations in adipokine secretion have
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been linked to the inhibition of insulin action in peripheral tissues like
the liver and skeletal muscle, but also to the development of diabetes-
associated complications like non-alcoholic fatty liver disease (NAFLD)
[2].
The prevalence of NAFLD is rapidly increasing along with the
pandemic increase in obesity [3]. The first step in the development of
NAFLD is lipid accumulation in hepatocytes. This increase in in-
tracellular lipids may result from higher rates of de novo lipogenesis
(DNL), a raised flux of fatty acids from adipose tissue to the liver and a
higher uptake of dietary lipids [4]. Clinical studies indicate that NAFLD
is strongly associated with hepatic insulin resistance and type 2 dia-
betes [5]. When hepatic steatosis is accompanied by tissue inflamma-
tion, necrosis and fibrosis, the disease proceeds from the more severe
non-alcoholic steatohepatitis to end-stage liver disease [6,7].
There is currently limited understanding on the importance of adi-
pokines for the development of NAFLD. Secreted frizzled-related pro-
tein (sFRP) 4, a member of regulators of the Wingless-type (Wnt) sig-
nalling pathway activity, is one of the adipokines showing an altered
expression and secretion from visceral adipose tissue (VAT) in obesity
and from patients with NAFLD [8–10]. Furthermore, circulating levels
of sFRP4 are increased in obesity and type 2 diabetes and associated
with the development of β-cell dysfunction [8,9]. Whereas in vitro
studies show direct effects of sFRP4 on insulin secretion by β-cells, little
is known on metabolic effects of sFRP4 in target tissues for insulin
action, such as the liver. Based on the increased expression of sFRP4 in
VAT from patients with NAFLD [10], and its association with insulin
resistance [8,11], we hypothesize that sFRP4 impacts on the liver by
interfering with insulin action and hepatic glucose and lipid metabo-
lism. This was examined in primary hepatocytes from metabolically
healthy C57Bl6 mice and from mice with systemic insulin resistance
and lipodystrophy, namely the aP2-SREBP-1c model [12,13]. Further-
more, we examined sFRP4 action in primary human myotubes.
2. Materials and methods
2.1. Study participants
We examined 36 normal-weight and 109 obese men from the pre-
viously described Obster and HepObster study conducted at the Ghent
University hospital according of the Declaration of Helsinki (Clinical
Trials Registration numbers NCT00740194 and B67020084018)
[10,14,15]. The study protocol was approved by the Ethics Committee
of Ghent University Hospital and participants gave written informed
consent. During surgery, biopsies from subcutaneous and visceral adi-
pose tissue were collected from the abdominal region, immediately
snap frozen in liquid nitrogen and stored at −80 °C for gene expression
analysis as described [10]. In addition, a liver biopsy was obtained from
54 obese participants, which was used for histological examination of
steatosis, lobular inflammation, ballooning and fibrosis as described
previously [10]. The histological data were used to calculate the stea-
tosis, activity and fibrosis score, which discriminates between NAFLD
and NASH [16], and the NAFLD activity score [7]. Overnight fasting
blood samples were collected prior to surgery for analysis of sFRP4, and
clinical measures as described [10,15]. HOMA-IR was calculated as
(fasting glucose [mmol/L]× (fasting insulin [μU/mL])/22.5)), and
HOMA2-%B was calculated as (20× fasting insulin [μU/ml])/(glucose
[mmol/l]-3.5).
2.2. Experimental animals
The animal experiments were approved by the Animal Care
Committee of the University Düsseldorf (approval number Az.84-
02.04.2015.A424, 2015), and performed according to the ‘Principle of
laboratory animal care’ (NIH publication No. 85-23, revised 1996) and
the German law on the protection of animals. We used male C57Bl6 and
transgenic mice that overexpress the transcriptional active form of
human SREBP-1c (aa 1–436) under the control of the adipocyte-specific
aP2 enhancer/promoter that were backcrossed on C57Bl6 for> 20
generations aged between 18 and 24weeks [12,13]. Mouse sFRP4
plasma levels were determined using a mouse sfrp4 ELISA kit (BIOZOL,
Eching, Germany) according to manufacturer's recommendations.
2.3. Isolation and culture of primary murine hepatocytes
Primary hepatocytes were isolated by a two-step collagenase per-
fusion protocol as described [13], and used within 24 h after isolation.
2.4. Culture of primary skeletal muscle cells
Primary human skeletal muscle cells were differentiated from
commercially available proliferating satellite cells (Lonza, Basel
Switzerland) as described [14]. Cells from at least four different male
and female healthy Caucasian donors aged between 16 and 41 years
were used.
2.5. Cell culture treatment
For signalling experiments, cell cultures were serum-starved for 4 h
prior to a 24 h incubation with 100 μg/l sFRP4 (R&D Systems,
Wiesbaden, Germany). This concentration was based on the circulating
levels in obese men [10]. When indicated, the cultures were incubated
with 10 nmol/l bortezomib (Merck, Darmstadt, Germany) for 30min
prior to sFRP4 addition, or with 100 nmol/l insulin (Sigma-Aldrich,
Taufkirchen, Germany) for additional 10min. In gluconeogenesis ex-
periments, hepatocytes were serum-starved for 20 h. For glycogen
synthesis, hepatocytes were glucose-starved for 90min prior to the
assay.
2.6. RNA extraction and analysis of gene expression
The quantification of sFRP4 gene expression in human VAT and SAT
was described [10]. Gene expression in murine adipose tissue, liver,
pancreas and m. gastrocnemius, and hepatocytes, was quantitated by
real-time PCR using gene-specific assays for acetyl-CoA carbocylase α
(Acaca), acyl-CoA thioesterase 2 (Acot2), carnitine palmitoyltransferase
1a (Cpt1a), carnitine palmitoyltransferase 2 (Cpt2), fatty acid synthase
(Fasn), Foxo1, Glucose-6-phosphatase, catalytic subunit (G6Pc), hepatic
nuclear factor 4α (Hnf4a), malic enzyme 1 (Me1), Mlx interacting
protein-like (Mlxipl, also known as carbohydrate-response element
binding protein 1, ChREBP), phosphoenolpyruvate carboxykinase 1
(Pck1), peroxisome proliferator activated receptor α (Ppara), ribosomal
protein S18 (RPS18), sFRP4 and sterol regulatory element-binding
transcription factor 1 (Srebp1c) (Thermofisher, Darmstadt, Germany) as
described [17].
2.7. Analysis of insulin action
The phosphorylation and abundance of components of insulin ac-
tion was examined by Western blotting as described elsewhere [14].
2.8. Analysis of sirtuin activity
Sirtuin (SIRT) activity was examined in cell lysates (5 μg protein)
using a luminescence-based SIRT-Glo™ assay system (Promega,
Mannheim, Germany) according to manufacturer's instructions.
2.9. Glycogen synthesis
Glycogen synthesis was determined by the incorporation of D-
[14C(U)]-glucose into glycogen as described [14].
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2.10. Gluconeogenesis
Glucose production in hepatocytes was determined by quantifica-
tion of the amount of glucose in the supernatant after the various
treatments as described [14]. Expression of G6pc and Pck1 was ex-
amined by real-time PCR as described under 2.6.
Determinants of mitochondrial function and glycolysis were ex-
amined using a Seahorse extracellular flux analyser (Agilent
Technologies, Waldbronn, Germany). Mitochondrial function in hepa-
tocytes was determined using the mito-stress as described [18]. In
primary myotubes, the mito-stress test was performed in the presence of
150 μmol/l palmitate coupled to BSA or the equivalent amount of BSA
[18]. Glycolysis was analyzed in myotubes using the glycolytic rate
assay [19]. The WAVE software (Agilent Technologies, version 2.6.0)
was used to calculate determinants of glycolysis and mitochondrial
function.
2.11. Fatty acid oxidation
Fatty acid oxidation was examined in primary hepatocytes and
myotubes by quantifying oxidation of [14C]-palmitate into 14CO2. The
14CO2 release was normalized to protein content presenting fatty acid
oxidation [19].
2.12. Analysis of cellular fatty acid uptake
Fatty acid uptake in skeletal muscle cells and primary hepatocytes
was detected as described [13,14,20].
2.13. De novo lipogenesis (DNL) in primary hepatocytes
The impact of sFRP4 on DNL in primary hepatocytes was de-
termined by the incorporation of 14C-acetate into lipids as described
[14].
2.14. Statistical analysis
Clinical study data were analyzed using SPSS Statistics (v25.0; IBM,
Armonk, NY, USA). The other data were analyzed with GraphPad Prism
(v7.04, GraphPad software, LaJolla, CA, USA). All data are expressed as
mean (95% CI) unless indicated otherwise. Differences between two
groups were calculated by Student t-test. In case of more groups,
differences were calculated by one- or two-way ANOVA followed by
Sidak correction for multiple comparisons. Variables with a skewed
distribution were log-transformed prior to linear regression analysis
with adjustments for age and/or BMI. A p-value of 0.05 was considered
as statistically significant.
2.15. Key resources table
Resource Source Identifier
Chemical
[14C]-palmitate
14C- acetate
acetyl-CoA
bortezomib
carbohydrate
Fatty acid
Glucose
palmitate
ProteinPeptide
insulin
IR
sfrp4
SREBP-1c
sterol regulatory element-binding transcription factor 1
3. Results
3.1. sFRP4 serum levels and gene expression in adipose tissue in obesity and
type 2 diabetes
We examined circulating sFRP4 levels and adipose tissue mRNA
levels in samples from a previously described clinical study on normal-
weight and obese men [14]. The characteristics of the study partici-
pants (normal-weight: n= 36; obese: n= 109, including n=51 with
type 2 diabetes) are summarized in Table 1. The obese men had a
higher body mass index (BMI), fasting insulin, alanine aminotransferase
(ALT) and gamma-glutamyl transferase (GGT) levels, and were insulin
resistant as estimated by homeostatic model assessment (HOMA-IR) (all
p < 0.001; except for GGT, p=0.01) versus normal-weight men. The
obese men with type 2 diabetes were older versus the participants
without type 2 diabetes (p < 0.001), and had higher Hb1Ac
(p < 0.01) and fasting glucose levels (p < 0.001).
Table 1
Patient characteristics.
Variable Normal weight Obese Obese+ type 2 diabetes P
N 36 58 51
Age, years 48.2 ± 13.6 42.1 ± 11.1⁎ 52.2 ± 9.9††† < 0.001
BMI, kg2/m 24.0 ± 2.76 41.2 ± 5.47⁎⁎⁎ 43.1 ± 6.88⁎⁎⁎ <0.001
HbA1c, % n.a. 5.78 ± 0.43 7.31 ± 1.66†† 0.009
Fasting glucose, mmol/l 4.83 (4.31–5.58) 5.33 (4.77–5.85) 7.00 (6.21–9.24)⁎⁎⁎,††† < 0.001
Fasting insulin, pmol/l 31.7 (21.0–43.5) 90.3 (55.8–163)⁎⁎ 135 (83.7–226)⁎⁎⁎ <0.001
HOMA-IR 0.89 (0.63–1.53) 2.96 (1.72–5.37) n.a. 0.011
HOMA2%B 67.5 (45.1–104) 118 (79.3–182) n.a. < 0.001
ALT, IU/l 23.0 (15.0–36.0) 48.0 (35.5–67.5)⁎⁎ 45.0 (27.0–63.0)⁎⁎ <0.001
AST, IU/L 20.0 (15.0–36.0) 28.0 (24.0–37.0) 32.0 (23.0–41.0)⁎⁎ 0.005
γGT, IU/L 25.0 (14.0–35.0) 40.0 (31.5–56.0)⁎ 39.0 (24.0–62.0)⁎⁎ 0.003
TG, mg/dl 133 (90.0–185) 175 (131–268) 161 (131–245) 0.037
The data are presented as mean ± SD in case of normally distributed datasets or as median (interquartile range) in case of skewed datasets. Differences between the
participant groups were calculated using ANOVA and Bonferroni correction for multiple comparisons.
BMI, body mass index; HOMA-IR, Homeostatic model assessment of insulin resistance; HOMA2%B Homeostatic model assessment of beta cell function; ALT, alanine
amino transferase; AST, aspartate aminotransferase; γGT, gamma glutamyl transferase; TG, triglycerides.
⁎⁎⁎ Indicate p < 0.001 for differences versus normal weight control men.
⁎⁎ Indicate p < 0.01 for differences versus normal weight control men.
⁎ Indicate p < 0.05 for differences versus normal weight control men.
††† Indicates p < 0.001 for differences between obese men with and without type 2 diabetes.
†† Indicates p < 0.01 for differences between obese men with and without type 2 diabetes.
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3.2. Correlates of sFRP4 serum and gene expression levels
Although we observed no statistically significant differences in cir-
culating sFRP4 levels among the three groups (Fig. 1A), sFRP4 in serum
associated with BMI (r= 0.211, p < 0.05) and triglycerides
(r= 0.200, p < 0.05) (Supplementary Tables 1, 2, Fig. 1B–C). In SAT,
sFRP4 mRNA was increased by 3.0- and 4.1-fold in biopsies from obese
men without and with type 2 diabetes, respectively (both p < 0.05
versus control) (Fig. 1D), and SAT SFRP4 mRNA levels associated with
BMI (r= 0.267, p < 0.05), fasting insulin (r= 0.320, p < 0.05),
HOMA2%B (r= 0.362, p < 0.05), and triglycerides (r= 0.433,
p < 0.001) (Supplementary Fig. 1).
In VAT, sFRP4 mRNA was increased by 3.2- and 3.4-fold in biopsies
from obese men without and with type 2 diabetes, respectively (both
p < 0.001 versus control) (Fig. 1E). VAT expression of sFRP4 corre-
lated with BMI (r= 0.507, p < 0.01), fasting insulin (r= 0.351,
p < 0.01), HOMA-IR (r= 0.348, p < 0.01), HOMA2%B (r= 0.237,
p < 0.01), and triglycerides (r= 0.376, p < 0.01). Furthermore, as-
sociations were found for ALT (r= 0.277, p < 0.01) and GGT
(r= 0.348, p < 0.01) (Fig. 1F–L). Adjusting for age had no profound
impact, whereas only the associations of VAT sFRP4 mRNA and GGT
(β=0.231, p < 0.01) and triglycerides (β=0.255, p < 0.01) re-
mained robust upon additional correction for BMI (Supplementary
Tables 1, 2).
When stratifying the cohort according to fatty liver disease state,
sFRP4 mRNA abundance in VAT was increased by 2.7- and 3.3-fold in
biopsies from men with NALFD and NASH, respectively
(Supplementary Fig. 2A) (both p < 0.001). Furthermore, sFRP4 ex-
pression associated with the NAFLD activity score (Supplementary
Fig. 2B) (r= 0.509, p < 0.001). Histological analysis further revealed
that sFRP4 expression was increased upon the presence of the defining
component of NAFLD, namely steatosis, lobular inflammation, bal-
looning, or fibrosis (Supplementary Fig. 2C–F).
3.3. sFRP4 impairs hepatic insulin action
Since the clinical data suggest that sFRP4 may interfere with insulin
action as well as hepatic lipid- and glucose metabolism, we first ex-
amined the effects of recombinant sFRP4 on insulin action in primary
murine hepatocytes isolated from metabolically healthy C57Bl6 mice.
Pre-incubation with sFRP4 impaired the insulin-mediated phosphor-
ylation of Akt-Ser473 by 46% (p < 0.01) (Fig. 2A), but had no sig-
nificant inhibitory effect on insulin-mediated Akt-Thr308 phosphor-
ylation (Fig. 2B). Furthermore, sFRP4 completely blocked the induction
of the insulin-mediated phosphorylation of the Akt-targets GSK3β-Ser9
and FoxO1-Ser256 (Fig. 2C–D). These effects of sFRP4 on insulin action
were not accompanied by changes in the basal phosphorylation of Akt-
Thr473, GSK3β-Ser9 and FoxO1-Ser256 or in the protein abundances of
Akt and GSK3β (Fig. 2A–C). However, sFRP4 incubation reduced the
protein abundance of FoxO1 by 55% (p < 0.001) (Fig. 2E). The lower
FoxO1 protein abundance suggests that sFRP4 suppresses the expres-
sion of FoxO1-regulated genes. Yet, besides phosphorylation, which
promotes nuclear exclusion of the protein, FoxO1-activity is regulated
by acetylation, and the SIRT-mediated deacetylation of FoxO1 increases
the DNA binding affinity and activity of the protein [21]. Treatment
with sFRP4 was found to reduce SIRT activity by 40% (p < 0.05) in
C57Bl6 hepatocytes (Fig. 2F), further supporting the notion that sFRP4
inhibits the expression of FoxO1-target genes.
More upstream in the insulin signalling cascade, we found that the
protein level of IRS2, a key regulator of the insulin signalling cascade,
was not affected by sFRP4 (Fig. 2G). Yet, IRS1 protein abundance was
reduced by 35% (p < 0.001) in hepatocytes treated with sFRP4 versus
untreated cells (Fig. 2H). Irs1 mRNA expression was not altered
(Fig. 2I). The sFRP4-mediated post-translational reduction in IRS1
protein abundance was absent when the cells were pre-treated with the
proteasome inhibitor bortezomib (BZ) (Fig. 3A). BZ alone had no effect
on IRS1 abundance (Fig. 3A). Furthermore, sFRP4 did not inhibit in-
sulin-mediated Akt-Ser473 and GSK3β-Ser9 phosphorylation in hepa-
tocytes treated with BZ (Fig. 3B and C). However, BZ did not restore
FoxO1 protein abundance and inhibition of insulin-mediated FoxO1-
Ser256 phosphorylation in sFRP4-treated hepatocytes (Fig. 3D and E).
3.4. Effects of sFRP4 on hepatic glucose and lipid metabolism
The gluconeogenic substrates pyruvate and lactate increased glu-
cose production by 1.5-fold versus untreated hepatocytes (p < 0.001)
(Fig. 4A). Insulin suppressed glucose production by 1.2-fold in the
presence of lactate and pyruvate (Fig. 4A). This insulin-mediated sup-
pression of substrate-induced glucose production was not observed in
hepatocytes exposed to sFRP4 (Fig. 4A). Insulin-mediated glycogen
synthesis was lower in hepatocytes exposed to sFRP4 prior to insulin
stimulation (p < 0.05) (Fig. 4B). Furthermore, insulin suppressed the
mRNA levels of Pck1 and G6pc by 1.7-fold (p < 0.05) and 2.2-fold
(p < 0.01), respectively (Fig. 4C and D). Incubating hepatocytes with
sFRP4 lowered G6pc expression by 40% (p < 0.05) (Fig. 5C). More-
over, sFRP4 treatment abrogated the reduction of Pck1 and G6pc
mRNA levels by insulin (Fig. 4C and D). This was not the case for the
stimulation of DNL by insulin. Insulin promoted acetate incorporation
into lipids by 1.5-fold in hepatocytes, and sFRP4 incubation enhanced
this further by 1.5-fold in an additive way (p < 0.05) (Fig. 4E). In line
with this observation, insulin and sFRP4 increased the mRNA levels of
fatty acid synthase (Fasn) by 2.7-fold (p < 0.001) and 2.5-fold
(p < 0.01), respectively, whereas an additive 5.0-fold increase in Fasn
mRNA levels (p < 0.001) was observed after combined sFRP4 and
insulin treatment (Supplementary Fig. 3). Exposing hepatocytes to
sFRP4 only had no effect on the gene expression of other regulators of
fatty acid metabolism, such as the transcription factors Foxo1, Hnf4a,
MlxipI, Ppara, Srebp1c, and the catabolic enzymes Acaca, Acot2, Cpt1a,
Cpt2, andMe1 (Supplementary Fig. 3). Insulin was found to increase the
mRNA levels Cpt1, Foxo1, Hnf4a, and MlxipI, and this was not observed
when hepatocytes were exposed to sFRP4 prior to insulin treatment
(Supplementary Fig. 3).
3.5. Effects of sFRP4 on hepatic mitochondrial function
The afore-mentioned data show that sFRP4 promotes de novo
Fig. 1. Serum sFRP4 levels and expression in human subcutaneous and visceral adipose tissue.
(A) Circulating serum sFRP4 levels from normal weight (control, n= 34) and obese men with (n=48) and without (n= 50) type 2 diabetes (T2D). Data are
expressed as dot plots showing the mean and 95% CI for each group. Differences among the groups were analyzed by ANOVA and Sidak's correction for multiple
comparisons.
(B,C) The graphs depict the regression lines and 95% confidence bands (dotted lines). The open dots represent normal weight men, the grey dots represent obese men
without T2D, and filled dots obese men with T2D.
(D, E) Gene expression of sFRP4 in SAT (a) and VAT (b) from normal weight (control, n= 13 [a], n= 28 [b]) and obese men with (n= 24 [a], n=43 [b]) and
without type 2 diabetes (T2D) (n= 20 [a], n=51 [b]). Data are expressed as dot plots showing the mean and 95% CI for each group. Differences among the groups
were analyzed by ANOVA and Sidak's correction for multiple comparisons. ***, p < 0.001 versus control. (F–L) Correlates between sFRP4 expression in VAT and
BMI (F), fasting glucose (G), fasting insulin (H), HOMA-IR (I), HOMA-2%B (J), triglycerides (K), and γGT (L). The standardized regression coefficient β and p-values
were calculated using linear regression analysis for the entire cohort. The graphs depict the regression lines and 95% confidence bands (dotted lines). The open dots
represent normal weight men, the grey dots represent obese men without T2D, and filled dots obese men with T2D.
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lipogenesis in hepatocytes, which could contribute to the development
of fatty liver, and the associated lipotoxic effects may include the in-
duction of mitochondrial malfunction. Therefore, we examined the ef-
fects of sFRP4 on living primary C57Bl6 hepatocytes using Seahorse
technology. As shown in supplementary Fig. 4, incubation with sFRP4
did not affect basal mitochondrial respiration, ATP production, and
proton leakage in hepatocytes. Maximal respiration, spare respiratory
capacity, and coupling efficiency were slightly increased by 14.4%
(p < 0.05), 21.8% (p < 0.05), and 22.5% (p < 0.01) by sFRP4
(Supplementary Fig. 4A–F). Oxidation of 14C-palmitate into CO2, as
well as 3H-palmitate uptake were unaffected by sFRP4 (Supplementary
Fig. 4G–H).
3.6. Effects of sFRP4 on skeletal muscle metabolism
In contrast to hepatocytes, sFRP4 did not impair the insulin-medi-
ated phosphorylation of Akt-Ser473, Akt-Thr308, and GSK3β-Ser9 in
myotubes, but the levels of phosphorylated FoxO1-Ser256 were de-
creased (Supplementary Fig. 5A–D). However, the FoxO1 protein levels
were not reduced in myotubes exposed to sFRP4 (Supplementary
Fig. 5E). Nevertheless, the incubation with sFRP4 decreased the protein
abundance of IRS1 by 64% (p < 0.01) (Supplementary Fig. 5F). As in
hepatocytes, this could not be ascribed to changes IRS1 gene expression
(Supplementary Fig. 5G), but was prevented by BZ treatment prior to
incubation with sFRP4 (Supplementary Fig. 6A). However, BZ did not
restore the inhibition of insulin-mediated FoxO1-Ser256 phosphoryla-
tion by sFRP4 in myotubes (Supplementary Fig. 6B). sFRP4 and BZ
exposure did not affect FoxO1 abundance (Supplementary Fig. 6C).
When examining mitochondrial function, we found that basal re-
spiration was 5-fold reduced in myotubes exposed to sFRP4
(p < 0.001) (Fig. 5A). Also, ATP production, proton leak and coupling
efficiency were reduced by 9.7- (p < 0.01), 2.7- (p < 0.05) and 1.8-
fold (p < 0.01) upon sFRP4 incubation (Fig. 5D–F). However, maximal
respiration or spare respiratory capacity were not affected by sFRP4
incubation of myotubes (Fig. 5B–C). The addition of palmitate prior to
the analysis of mitochondrial function increased basal respiration,
maximal respiration, ATP-production and proton leak by 1.4-
(p < 0.001), 1.4- (p < 0.001), 1.3- (p < 0.01), and 1.5-fold
(p < 0.01), respectively (Fig. 5A–F). The incubation with sFRP4 low-
ered the palmitate-induced increases in basal respiration and proton
leak by 25% (p < 0.05) and 38% (p < 0.05) (Fig. 5A, E), respectively,
whereas sFRP4 had no effect on palmitate-induced maximal respiration,
spare respiratory capacity, ATP production, and coupling efficiency
(Fig. 5B–D, F). Conventional fatty acid oxidation assays confirmed that
sFRP4 does not affect the oxidation of 14C-palmitate to CO2 (Fig. 5G).
The ECAR's recorded during the Seahorse-based analysis of mi-
tochondrial function in myotubes showed that sFRP4 induces a shift
toward a more glycolytic phenotype (Supplementary Fig. 7). In a gly-
colytic rate assay, sFRP4 promoted a 3.2-fold increase in the ratio be-
tween glycolytic and mitochondrial oxidative capacity (p < 0.001)
(Fig. 5H). Furthermore, sFRP4 increased the basal proton efflux rate
and basal glycolysis 2.5- (p < 0.01) and 2.8-fold (p < 0.001), re-
spectively (Fig. 5I–J). Accordingly, the percentage of protons derived
from glycolysis was increased from 81.4% to 91.3% upon sFRP4
treatment of myotubes (Fig. 5K). Also, compensatory glycolysis,
examined after injection with rotenone/antimycin A, was increased by
2.2-fold (p < 0.05) in sFRP4-treated myotubes (Fig. 5L).
3.7. Effects of sFRP4 action in hepatocytes from a mouse model with
lipodystrophy
Finally, we examined whether the effects of sFRP4 are affected by
massive lipid overload in hepatocytes. Therefore, we used hepatocytes
isolated from the well-described aP2-SREBP-1c mouse model that is
characterized by a complete loss of adipose tissue and fatty liver with
systemic insulin resistance without any dietary intervention
(Supplementary Table 3) [13]. Furthermore, the hepatocytes isolated
from these mice are characterized by the accumulation of large lipid
droplets [13]. Circulating sFRP4 levels in aP2-SREBP-1c mice were
lower versus C57Bl6 control mice (aP2-SREBP-1c: 36.38 (33.24–39.51)
μg/l versus C57Bl6: 44.95 (40.29–49.61) μg/l, p=0.002), thereby
confirming VAT as source for sFRP4 release (Supplementary Fig. 8A).
Gene expression of sFRP4 in m. gastrocnemius, liver, and pancreas was
comparable between the two mouse strains (Supplementary Fig. 8B).
Hepatocytes from aP2-SREBP-1c mice showed a higher DNL rate
compared to C57Bl6 (Fig. 6A vs 4E), which was not significantly af-
fected by insulin treatment or pre-incubation with sFRP4 (Fig. 6A).
Mitochondrial function in aP2-SREBP-1c hepatocytes was compar-
able to C57Bl6 hepatocytes, and was not affected by sFRP4
(Supplementary Fig. 9A). Furthermore, sFRP4 did not interfere with
palmitate uptake and oxidation (Supplementary Fig. 9G and H).
In the absence of statistically significant effects on IRS1 protein
abundance in aP2-SREBP-1c hepatocytes (Fig. 6B), sFRP4 severely im-
paired the insulin-mediated phosphorylation of components of the Akt
signalling pathway. In aP2-SREBP-1c hepatocytes, sFRP4 impaired in-
sulin-mediated Akt-Ser473 phosphorylation by 55% (p < 0.001)
versus 46% in C57Bl6 hepatocytes (Figs. 6C and 2A), and completely
abrogated insulin-mediated Akt-Thr308 phosphorylation in contrast to
C57Bl6 hepatocytes (Fig. 6D). As in C57Bl6 hepatocytes, sFRP4 abro-
gated the induction of GSK3β-Ser9 phosphorylation (Fig. 6E). Fur-
thermore, sFRP4 reduced FoxO1 abundance when normalized to
GAPDH by 83% (Fig. 6F). Consequently, the absolute levels of FoxO1-
Ser256 phosphorylation were lower in aP2-SREBP-1c hepatocytes that
were exposed sFRP4 versus untreated cells (Fig. 6G). However, FoxO1-
Ser256 phosphorylation levels when normalized to FoxO1 protein level
were increased by insulin (Fig. 6H).
4. Discussion
Here we showed that sFRP4 expression is increased in VAT from
obese men and associated with insulin resistance and triglycerides. In
vitro studies on hepatocytes showed that sFRP4 disturbed insulin action
by reducing the protein abundances of IRS1 and FoxO1 and blunting
Akt signalling pathway. The latter effect was even stronger in hepato-
cytes isolated from aP2-SREBP-1c mice with lipodystrophy and ectopic
hepatic lipid accumulation. The inhibition of insulin action in hepato-
cytes was selective since insulin-stimulated DNL was not impaired by
sFRP4 in hepatocytes isolated from both C57Bl6 and aP2-SREBP1c
mice. Furthermore, we showed that sFRP4 strongly increased basal
glycolysis in myotubes, which may aggravate hepatic steatosis and
Fig. 2. sFRP4 impairs insulin signalling in primary hepatocytes from C57Bl6 mice.
Representative Western blots and graphs show the effects of 100 μg/l sFRP4 for 24 h on insulin-stimulated phosphorylation of Akt-Ser473 (A), Akt-Thr308 (B),
GSK3β-Ser9 (C), and FoxO1-Ser256 (D), and the effects of sFRP4 on the protein abundances of FoxO1 (E), IRS2 (G), and IRS1 (H), sirtuin (SIRT) activity (G), and gene
expression of Irs1 (I). The scattered bar graphs indicate the mean ± SD for the phosphorylation levels and abundances obtained in four independent experiments
using hepatocyte preparations from different mice. The phosphorylation levels of Akt and GSK3β were corrected for the abundance of the non-phosphorylated
protein and GAPDH, whereas the phosphorylation levels of FoxO1 were corrected for the abundance of GAPDH only. The values obtained in hepatocytes incubated
for 10min with 100 nmol/l insulin only (A–G) or untreated cells (H) were considered as control and set at 100% or 1. The effects of sFRP4 and insulin on
phosphorylation levels were analyzed by two-way ANOVA with Sidak's correction for multiple comparisons. The effect of sFRP4 on protein abundance and Irs1 gene
expression was evaluated using a student's t-test. */§p < 0.05, **/§§p < 0.01 and ***p < 0.001; * with vs without insulin stimulation, § with vs without sFRP4
incubation.
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associated insulin resistance.
The in vitro data are corroborated by findings in clinical studies on
normal-weight to slightly overweight participants, which showed that
systemic sFRP4 interfered with insulin secretion, associated with mea-
sures of insulin resistance, such as HOMA-IR [8,22], clamp-measured
insulin sensitivity [23], and the oGTT-based insulin sensitivity index
[9], as well as triglycerides [8,11]. Although circulating sFRP4 levels
displayed weak associations with BMI and triglycerides, an increase in
patients with type 2 diabetes as observed in previous studies [8,11,23]
was not observed in our cohort enrolling normal-weight men and men
with extreme obesity. A potential cause for this discrepancy may be the
ethnical background of the study population. Two of the afore-men-
tioned studies reporting increased sFRP4 levels were conducted on
normal-weight Chinese [22] or Asian-Indian [8] patients with type 2
diabetes, whereas the third study reports on findings collected in a
rather small group (n= 12) of slightly overweight probands of both
Caucasian and African-American background [23]. Besides, one should
note that our study was conducted on men. Because the circulating
sFRP4 levels are comparable between Chinese men and women [22],
and adjusting for sex did not impair the reported relations between
circulating sFRP4 and insulin resistance in two reports [8,9], it seems
unlikely that the sole inclusion of male probands could affect the in-
terpretation of the data. In line with another study [24], we confirmed
that the expression of sFRP4 in adipose tissue is increased in obesity,
and that the expression levels associated with BMI, insulin resistance,
insulin secretion and triglycerides. This observation and the previously
reported increase in sFRP4 expression in adipose tissue in patients with
NAFLD [10] strongly support the idea that the liver is an important
target tissue for sFRP4 action.
A key finding of this study represents the detrimental effect of sFRP4
on hepatic insulin action. The in vitro experiments showed that sFRP4
disturbed insulin signalling at multiple levels. One level may involve
IRS1 protein abundance reduction in metabolically healthy hepatocytes
and myotubes. One may ascribe the reduction in IRS1 abundance to
activation of the proteasome. Inhibition of proteasome activity pre-
vented the sFRP4-mediated reduction in IRS1 protein abundance and
Fig. 3. Effect of the proteasome inhibitor bortezomib on sFRP4 action in hepatocytes.
The graphs and representative Western blots show the effects of sFRP4 with or without bortezomib (BZ) pretreatment on IRS1 protein abundance (A), on the insulin-
stimulated phosphorylation of Akt-Ser473 (B), GSK3β-Ser9 (C), and FoxO1-Ser256 (D), and the protein abundance of FoxO1 (E). The scattered bar graphs indicate
the mean ± SD for the phosphorylation levels and abundances obtained in five independent experiments using hepatocyte preparations from different mice. The
phosphorylation levels were corrected for the abundance of GAPDH. The values obtained in hepatocytes incubated for 10min with 100 nmol/l insulin only were
considered as control and set at 100%. The effects of BZ, sFRP4 and insulin on phosphorylation levels and protein abundances were analyzed by ANOVA with Sidak's
correction for multiple comparisons. */§/‡p < 0.05, **p < 0.01 and ***/‡‡‡p < 0.001; * with vs without insulin stimulation, § with vs without sFRP4 incubation,
‡ with vs without BZ incubation.
Fig. 4. Effect of sFRP4 on glucose metabolism and lipogenesis in primary hepatocytes from C57Bl6 mice.
Primary murine hepatocytes were incubated with sFRP4 for 24 h or kept untreated prior to the analysis of glucose production (n=4) (A), glycogen synthesis (n= 6)
(B), gene expression of G6pc (n= 4) (C) and Pck1 (n=4) (D), and lipogenesis (n= 5) (E). The values obtained for untreated cells in the glucose production
experiments (A, C, D) were considered as control and set at 1. The scattered bar graphs depict the data as mean ± SD. The effects of sFRP4 and insulin were analyzed
by two-way ANOVA with Sidak's correction for multiple comparisons. */§p < 0.05 and ***/§§§p < 0.001; * with vs without insulin stimulation, § with vs without
sFRP4 incubation.
T. Hörbelt, et al. BBA - Molecular Basis of Disease 1865 (2019) 2671–2684
2679
(caption on next page)
T. Hörbelt, et al. BBA - Molecular Basis of Disease 1865 (2019) 2671–2684
2680
the inhibition of the phosphorylation of Akt-Ser473 and GSK3β-Ser9 in
hepatocytes. This suggests that the amount of IRS1 is critical for acti-
vation of the Akt/GSK3β arm of the insulin signalling cascade in he-
patocytes. However, in myotubes there was no inhibition of insulin-
mediated phosphorylation of Akt and GSK3β by sFRP4 despite reduc-
tions in IRS1 protein abundance. It remains to be investigated what
underlies the tissue-specific inhibition of insulin action by sFRP4. sFRP4
is a modulator of the activity of the canonical Wnt signalling pathway,
which promotes the stabilization of β-catenin and stimulation of gene
expression through interaction with the T-cell factor transcription fac-
tors [25]. Activation of Wnt signalling is initiated by binding of the
Wnt-ligands to the frizzled receptors, whereas inactivation is regulated
by the binding of the sFRP's, including sFRP4 to the Wnt-ligands [25].
Since at least 19 different Wnt-ligands have been identified that can
bind to at least 10 different Frizzled receptors [25], one may speculate
that differences in the tissue distribution of Wnt-ligands and Frizzled
receptors underlie the differences in sFRP4 signalling between hepa-
tocytes and myotubes.
Proteasome inhibition did not prevent the sFRP4-mediated reduc-
tion in FoxO1 protein abundance in hepatocytes. This observation in-
dicates an additional level via which sFRP4 disturbs insulin action.
FoxO1 regulates gluconeogenic gene expression and activates hepatic
glucose production in fasting periods, which can be suppressed de-
pending on insulin by Akt activation [26]. In response to sFRP4, both
the protein abundance and insulin-mediated phosphorylation of FoxO1
were reduced. Consequently, when sFRP4 treatment is combined with
insulin stimulation in C57Bl6 hepatocytes, the absolute phosphoryla-
tion levels of FoxO1 are not further increased, and one may expect that
the already lower expression of FoxO1-regulated genes is not further
suppressed. Independent from phosphorylation, the activity of FoxO1 is
additionally controlled by acetylation. Increases in CBP/p300-mediated
FoxO1-acetylation, reduces its affinity to the DNA. On the other hand,
deacetylation of FoxO1, as mediated by the SIRT family of deacetylases,
increases the DNA-binding affinity of FoxO1. Thus, the sFRP4-mediated
reduction in SIRT activity in hepatocytes may further reduce FoxO1
activity. One may assume that the lower expression of the FoxO1-
regulated genes G6pc and Pck1 in sFRP4-treated C57Bl6 hepatocytes
can be ascribed to reductions in FoxO1 activity. The reduction in FoxO1
activity may also indicate an attempt to compensate for sFRP4 inter-
ference with insulin signalling at FoxO1. Constitutively active hepatic
FoxO1 has been associated with impaired fasting glucose, hyper-
insulinemia and increased triglyceride levels and steatosis in mice.
Furthermore, upon liver-specific deletion of FoxO1, gluconeogenesis
was reduced and hyperglycemia improved in obese mice [27,28]. Mice
with liver-specific loss of either the insulin receptor, Akt or IRS-1/IRS-2
showed increased FoxO1-mediated hepatic glucose production along
with severe insulin resistance and glucose intolerance, while if there
was simultaneous ablation of FoxO1 in the liver, these metabolic dis-
orders were restored, leading to suppression of hepatic glucose pro-
duction in response to insulin and improved glucose tolerance [29,30].
These studies proposed an additional IR-, IRS- and Akt-independent
mechanism through which FoxO1 regulates hepatic glucose production
[30].
Importantly, the stimulation of DNL by insulin was not inhibited by
sFRP4. Rather, sFRP4 even enhanced the stimulation of DNL in hepa-
tocytes. The sFRP4-mediated decrease in FoxO1 protein expression may
contribute to this enhanced lipogenesis, since studies on isolated he-
patocytes demonstrated that inhibition of FoxO1 as such is sufficient to
drive lipogenesis [31]. However, one should also note that the selective
inhibition of the activation of Akt signalling by insulin in concert with
the stimulation of lipogenesis closely resembles the paradox of selective
hepatic insulin resistance in type 2 diabetes as proposed by Brown and
Goldstein [32]. Here, insulin signalling via the Akt/FoxO1-pathway is
impaired. This results in impaired suppression of hepatic gluconeo-
genesis by insulin, but promotes the other main action of insulin in the
liver, namely the stimulation of DNL via the transcription factor SREBP-
1c [32]. Increased DNL can result in hepatic lipid accumulation, which
on its turn is highly associated with insulin resistance [13,17].
Here, we also examined the effects of sFRP4 on insulin action in
hepatocytes from lipodystrophic aP2-SREBP-1c mice. In humans, lipo-
dystrophy leads to excessive ectopic storage of fat in the liver associated
with increased liver DNL, severe hepatic insulin resistance, dyslipi-
daemia, hyperglycaemia, hypertriglyceridemia, hyperinsulinemia and
NAFLD [33–35]. The aP2-SREBP-1c mice are characterized by massive
hepatic lipid accumulation due to the complete lack of adipose tissue
and thus the absence of adipose tissue lipid storage capacity and sys-
temic insulin resistance associated with reduced insulin action but in-
creased hepatic lipogenesis [12,13,36]. Accordingly, we found that
DNL in lipodystrophic mice was higher than in C57Bl6, but neither
insulin nor sFRP4 further increased DNL in aP2-SREBP1c hepatocytes as
seen in hepatocytes of metabolic healthy C57Bl6 mice. In the absence of
an effect on lipid uptake and oxidation, sFRP4 incubation caused a
more severe inhibition of the insulin signalling pathway to Akt in aP2-
SREBP-1c compared to C57Bl6 hepatocytes. This suggests that hepatic
lipid accumulation aggravates the detrimental effects of sFRP4 on he-
patic insulin sensitivity.
Apart from the effects of sFRP4 on lipogenesis found in hepatocytes
from metabolically healthy C57Bl6 hepatocytes mice, also indirect ef-
fects of sFRP4 may contribute to hepatic lipid accumulation. In myo-
tubes, sFRP4 caused a marked increase in glycolysis. The resulting
lactate, using the Cori cycle, may be converted to glucose in the liver,
which on its turn can be oxidized, stored as glycogen or converted into
lipids. The in vitro studies showed that sFRP4 did not impair hepatocyte
mitochondrial function, and that it inhibits the stimulation of glycogen
synthesis by insulin. Therefore, one may speculate that enhanced gly-
colysis in skeletal muscle may contribute to enhanced lipid accumula-
tion by enhancing lipogenesis. However, further in vivo studies are
needed to support this.
The increased sFRP4 expression in subjects with obesity or type 2
diabetes, which was also reported by others [24,37], may suggest that
sFRP4 acts as an adipokine. Accordingly, the analysis of plasma samples
from lipodystrophic aP2-SREBP-1c mice lacking adipose tissue showed
a decrease in circulating sFRP4 levels compared to C57Bl6 mice.
However, the data also showed that adipose tissue is not the only source
for systemic sFRP4. This confirmed other reports that sFRP4 is also
expressed and/or secreted in other tissues, such as the liver, the pan-
creas and skeletal muscle [9,38–41]. However, it remains to be in-
vestigated whether a deregulated expression of sFRP4 in the context of
Fig. 5. Effect of sFRP4 on mitochondrial function, palmitate oxidation and glycolysis in primary human myotubes.
(A–F) Determinants of mitochondrial function in primary human myotubes. The bar graphs depict basal respiration (A), maximal respiration (B), spare respiratory
capacity (C), ATP production (D), proton leak (E), and coupling efficiency (F) as calculated from a Seahorse mito-stress test in primary human skeletal muscle cells
that were exposed to sFRP4 for 24 h or kept untreated. The mito-stress assay was performed after the addition of BSA or palmitate, which were added immediately
before the start of the Seahorse analysis. The data are the mean ± SD of at least 4 independent experiments using primary skeletal muscle cells from 3 different
donors. (G) Effect of sFRP4 on the 14C-palmitate oxidation in primary human myotubes that were incubated with sFRP4 or not. Data are the mean ± SD for the
oxidation of 14C-palmitate of 6 independent experiments. (H–L) Determinants of glycolytic function in primary human myotubes. The bar graphs depict the ratio
between glycolytic PER and baseline mitochondrial OCR (H), basal PER (I), basal glycolysis (J), %PER from glycolysis (K), and compensatory glycolysis (L) as
calculated from a Seahorse glycolytic rate assay in primary human skeletal muscle cells that were exposed to sFRP4 for 24 h or kept untreated. The data are the
mean ± SD of five independent experiments using primary skeletal muscle cells from 3 different donors. */§p < 0.05, **/§§p < 0.01 and ***/§§§p < 0.001; *
with vs without palmitate incubation, § with vs without sFRP4 incubation.
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obesity and type 2 diabetes is also found in these non-adipose tissues. At
least in aP2-SREBP-1c mice, we found no upregulation in non-adipose
sFRP4 expression versus the C57Bl6 model.
Collectively, we show an association between sFRP4 expression in
adipose tissue with insulin sensitivity and triglyceride levels in human.
In vitro studies on hepatocytes showed that sFRP4 selectively inhibits
the insulin signalling pathway regulating glucose metabolism, while
enhancing the stimulation of DNL. The latter may be further enhanced
by increased glycolysis in sFRP4-treated myotubes. Finally, as proof of
principle in hepatocytes isolated from a lipodystrophic mouse model
with hepatic lipid accumulation, we found that sFRP4 further ag-
gravates insulin action. Based on these data and the notion that sFRP4
levels are increased already before the onset of type 2 diabetes [9],
sFRP4 may be an attractive target to mitigate pathophysiological
changes that occur during the development of type 2 diabetes and fatty
liver disease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbadis.2019.07.008.
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